Dianthus Therapeutics targets severe autoimmune diseases with DNTH103. Read more on DNTH's promise amid competitive ...

Innate Pharma (IPHA) announced review of its January 2016 research collaboration and license agreement with Sanofi (SNY): As previously ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announce review of their January 2016 ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment ...

We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a ...

Sanofi (SNY) stock slips as the company's asthma therapy amlitelimab fails in a Phase 2 trial, despite its plans to evaluate ...